Navigation Links
Boehringer Ingelheim Enrolls First Patients in Pivotal Phase 3 Interferon-Free Hepatitis C Trial Program
Date:1/17/2013

ronic HCV, accounting for 15,000 deaths in the United States in 2007.

About Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringerus.

*Sustained virologic response (SVR) 12 and 24 weeks following treatment completion


'/>"/>
SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
2. Boehringer Ingelheim Announces Equine Research Awards
3. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
4. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
5. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
6. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
7. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
8. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
9. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
10. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
11. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... British Columbia and MENLO PARK, ... Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), ... of new cancer therapies, today announced its financial results ... provided an overview of recent Company highlights and expected ... host a business update conference call and live webcast ...
(Date:9/3/2015)... 3, 2015 Report Details ... that Market, its R&D and Sales Potentials ... of cancer-treating medicines? Visiongain,s new report gives you revenue predictions ... you discover financial data, R&D trends, opportunities, interviews and revenue ... analysis you see forecasted sales to 2025 at overall world ...
(Date:9/3/2015)... About cardiovascular implants ... or blockage of blood vessels. Cardiac disease is ... cholesterol, and high blood pressure. Coronary artery disease, ... failure are some of the major cardiac diseases. ... coronary arteries, is one of the most common ...
Breaking Medicine Technology:DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 2DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 3DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 4DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 5DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 6DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 7DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 8World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 2World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 3World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 4World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 5World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 6World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 7Global Cardiovascular Implants Market 2015-2019 2
(Date:9/4/2015)... Marietta, GA (PRWEB) , ... September 04, 2015 , ... ... team is in desperate need of new apparel. In an effort to assist the ... around Marietta, has launched a charity drive to raise funds for the new uniforms. ...
(Date:9/4/2015)... ... September 04, 2015 , ... Keeping mold top of mind is ... is quite common. Mold can grow anywhere - on carpet, clothing, food, paper, and ... excessive moisture and water in the home is key to preventing mold growth, which ...
(Date:9/4/2015)... , ... September 04, 2015 , ... Many consumers are looking for a quick and ... their solution. , The patent-pending K Med Cups provide a quick and simple way to ... relieve a cold, flu or cough. As a result, they enhance comfort and health. The ...
(Date:9/4/2015)... ... 2015 , ... Having access to a doctor can sometimes be a challenge ... unnecessary emergency room visits which affects hospitals’ abilities to provide quality service to those ... solution to alleviate this problem has recently presented itself, the new telemedicine platform and ...
(Date:9/4/2015)... ... 2015 , ... Compliance officers deal with many high-risk issues, ... self-referral law. “Stark Law DOs and DON’Ts: Best Practices for Your Physician ... will detail which deals are attracting the most government scrutiny and what are ...
Breaking Medicine News(10 mins):Health News:The Jones Agency Serves Up a Charity Drive to Fund New Uniforms for the Sprayberry High School Girls Volleyball Team 2Health News:The Jones Agency Serves Up a Charity Drive to Fund New Uniforms for the Sprayberry High School Girls Volleyball Team 3Health News:September is Mold Awareness Month 2Health News:September is Mold Awareness Month 3Health News:September is Mold Awareness Month 4Health News:Redesigned Packaging for Powdered Medicinal Mix Invented by InventHelp® Client (CBA-2637) 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 2Health News:Telemedicine Platform DocChat Announces Launch Offering a Way for Patients to Consult Doctors and Receive Prescriptions 24/7 3Health News:Sept. 17 Webinar to Offer Best Practices for Physician Contracts 2
... Team ( www.mobilemassageteam.com ), a leading provider of ... and special affairs, today announced that the company will be ... Beyond Breast Cancer ( http://www.lbbc.org /) ... p.m. on the steps of the Philadelphia Museum of Art. ...
... 15 Quest Diagnostics Incorporated (NYSE: ... patients and their physicians to share diagnostic laboratory ... enable physicians who use Quest Diagnostics, Care360(TM) patient-centric ... request, diagnostic laboratory test results in a HIPAA-compliant ...
... Corporation, (OTC Bulletin Board: CDXC) a leader in ... financial results for the 2009 first quarter. On ... Generally Accepted Accounting Principles (U.S. GAAP), ChromaDex announced ... $0.01 per share for the thirteen week period ...
... (NYSE Amex: PTN ) announced today results for its ... of $0.1 million, or $0.00 per basic and diluted share, for ... of $5.1 million, or $0.06 per basic and diluted share, for ... ended March 31, 2009 were $5.2 million, compared to $0.7 million ...
... results to establish Group B Strep colonization of pregnant ... infections in newbornsGBS PNA FISH shown to detect up ... (1)WOBURN, Mass. and VEDBAEK, Denmark, May 15 AdvanDx ... PNA FISH(R) for detection of Streptococcus agalactiae , ...
... years, it has been known that aspirin is beneficial ... which of the many different types of aspirin is ... researchers led by Dr. Sean Nordt from the University ... aspirin to a group of volunteer research subjects: regular ...
Cached Medicine News:Health News:Quest Diagnostics to Connect to Microsoft HealthVault and Empower Patients and Physicians to Share Diagnostic Laboratory Test Results Online 2Health News:Quest Diagnostics to Connect to Microsoft HealthVault and Empower Patients and Physicians to Share Diagnostic Laboratory Test Results Online 3Health News:ChromaDex Reports 2009 Q1 Financial Results 2Health News:ChromaDex Reports 2009 Q1 Financial Results 3Health News:Palatin Technologies, Inc. Reports Fiscal Year 2009 Third Quarter Results; Teleconference and Webcast to be held on May 15, 2009 2Health News:Palatin Technologies, Inc. Reports Fiscal Year 2009 Third Quarter Results; Teleconference and Webcast to be held on May 15, 2009 3Health News:Palatin Technologies, Inc. Reports Fiscal Year 2009 Third Quarter Results; Teleconference and Webcast to be held on May 15, 2009 4Health News:Palatin Technologies, Inc. Reports Fiscal Year 2009 Third Quarter Results; Teleconference and Webcast to be held on May 15, 2009 5Health News:Palatin Technologies, Inc. Reports Fiscal Year 2009 Third Quarter Results; Teleconference and Webcast to be held on May 15, 2009 6Health News:AdvanDx Receives FDA 510(k) Clearance for GBS PNA FISH(R) for Rapid Detection of Group B Strep from Lim Broths 2Health News:AdvanDx Receives FDA 510(k) Clearance for GBS PNA FISH(R) for Rapid Detection of Group B Strep from Lim Broths 3
... MacularProtect delivers levels of nutrients ... and macular health in the ... The National Eye Institute. MacularProtect ... lutein, an antioxidant found to ...
... MacularProtect Complete® is a scientifically advanced ... for macular and full body health. ... AREDS clinical trial and other advanced ... component that provides a broad foundation ...
... AREDS formula is the one and only ... effective in the 10-year National Institutes of ... (AREDS). , PreserVision® AREDS is a high ... antioxidant vitamins A, C, E and select ...
... is a scientifically advanced multinutrient ... visual and full body health. ... nutrients, including a diverse array ... lutein, lycopene and OptiBerry and ...
Medicine Products: